Emotion and Attention in Alzheimer's Disease (ATEMMA)

Grenoble Alpes University Hospital Center (CHU)

Status: Completed

Conditions: Alzheimer Disease

Treatments: Behavioral: Facial expression recognition task

Study type: Interventional

Funder types: Other

Identifiers

NCT03971994

2018/113

2018-A02945-50 (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to investigate the existence of emotional attention impairments in Alzheimer's Disease, in correlation with amygdala and attention networks alterations. To this end, functional and structural neuroimaging will be used. A face expression recognition task, along with eyetracking, will be used to assess emotional attention impairments.

Enrollment: 41 patients

Sex: All

Ages: 18 to 95 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy volunteers :

  • Affiliation to social security
  • Medical examination before study participation
  • No contraindication to MRI
  • Informed consent signed
  • Young adults older than 18 years and younger than 40 years
  • Healthy old adults older than 65 years and younger than 95 years
  • Visual acuity allowing normal perception of stimuli or corrected to normal vision

• Patients with Alzheimer's Disease :

  • Affiliation to social security
  • Medical examination before study participation
  • No contraindication to MRI
  • Informed consent signed
  • Patients with Alzheimer's Disease at mild or moderate stage (National Institute on Aging and Alzheimer's Association criteria), diagnosed at Grenoble CMRR (Centre Mémoire de Ressources et de Recherche)
  • Patients older than 65 years and younger than 95 years
  • MMSE (Mini-Mental State Examination) > 18/30
  • Ability to understand study instructions and give an informed consent
  • Visual acuity allowing normal perception of stimuli or corrected to normal vision

Exclusion criteria

• Every participant having a vascular stent implanted less than 6 weeks before study
• Every participant having a biomedical material implanted that is considered "unsafe" in the list: http://www.mrisafety.com/TheList_search.asp
• Every acquisition procedure not respecting required conditions by the "conditional" usage in a participant having a biomedical material implanted that is considered "conditional" in the list: http://www.mrisafety.com/TheList_search.asp
• Every subject having a biomedical material such as a cardiac, neuronal or sensorial stimulator (cochlear implant because of demagnetization, electrode heating or artefact risk) or a ventricular drain without trained medical or paramedical support during MRI for these participants
• Ferromagnetic object inside the eye or the skull, close to nervous structures (displacement and complications risk such as eye or brain damage)
• Claustrophobia
• Psychiatric (e.g., bipolar disorder) or neurological pathology (e.g., epilepsy, Parkinson's Disease) other than Alzheimer's Disease
• Non cooperating participant
• Severe and uncontrolled affection: cardiac, respiratory, haematological, renal, hepatic, cancerous
• Participation to other research protocols with exclusion period or MRI during the past weel
• Drug therapy likely to modulate brain activity : neuroleptics, lithium, etc...
• Alcohol ingestion before study
• Participants concerned by articles L1125-5 to L1121-8 of CSP (Code de la Santé Publique) (pregnant or nursing women, underage or protected adult, person under administrative or judicial oversight
• Participant receiving more than 4500 euros for his participation to other studies involving human person during the past 12 months before this study
• Participant unable to be contacted in case of emergency
• Inability to understand study instructions or give an informed consent

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

41 participants in 3 patient groups

Young adults

Active Comparator group

Description:

Participants aged between 18 and 40 years old.

Treatment:

Behavioral: Facial expression recognition task

Healthy old adults

Active Comparator group

Description:

Participants aged between 65 and 95 years old.

Treatment:

Behavioral: Facial expression recognition task

Patients with Alzheimer's Disease

Experimental group

Description:

Participants aged between 65 and 95 years old with a diagnosis of Alzheimer's Disease.

Treatment:

Behavioral: Facial expression recognition task